Finding the right time for anti-inflammatory therapy in COVID-19

doi:10.1016/j.ijid.2020.09.1454

Comment

. 2020 Dec:101:247-248.

doi: 10.1016/j.ijid.2020.09.1454. Epub 2020 Oct 1.

Finding the right time for anti-inflammatory therapy in COVID-19

Giovanni de Simone¹, Costantino Mancusi²

Affiliations

¹ Department of Advanced Biomedical Science, Federico II University of Naples, Naples, Italy. Electronic address: simogi@unina.it.
² Department of Advanced Biomedical Science, Federico II University of Naples, Naples, Italy.

PMID: 33011285
PMCID: PMC7528747
DOI: 10.1016/j.ijid.2020.09.1454

Comment

Finding the right time for anti-inflammatory therapy in COVID-19

Giovanni de Simone et al. Int J Infect Dis. 2020 Dec.

. 2020 Dec:101:247-248.

doi: 10.1016/j.ijid.2020.09.1454. Epub 2020 Oct 1.

Authors

Giovanni de Simone¹, Costantino Mancusi²

Affiliations

¹ Department of Advanced Biomedical Science, Federico II University of Naples, Naples, Italy. Electronic address: simogi@unina.it.
² Department of Advanced Biomedical Science, Federico II University of Naples, Naples, Italy.

PMID: 33011285
PMCID: PMC7528747
DOI: 10.1016/j.ijid.2020.09.1454

No abstract available

PubMed Disclaimer

Figures

**Figure 1**
The three stages of COVID-19, as proposed by Siddiqi and Mehra (Siddiqi and Mehra, 2020), with suggested pathophysiologically appropriate stage-related treatment. The larger the size of the characters within the figure, the stronger the recommendation. The duration of the stages is indicative and can vary substantially. The criteria suggested by Langer-Gould et al. (2020) might substantially help to determine the shift from stage I to stage II.

See this image and copyright information in PMC

Comment in

Editorial Response to Drs. Simone and Mancusi.
Langer-Gould A. Langer-Gould A. Int J Infect Dis. 2020 Dec;101:367. doi: 10.1016/j.ijid.2020.09.1455. Epub 2020 Oct 2. Int J Infect Dis. 2020. PMID: 33017695 Free PMC article. No abstract available.

Comment on

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A, Smith JB, Gonzales EG, Castillo RD, Figueroa JG, Ramanathan A, Li BH, Gould MK. Langer-Gould A, et al. Int J Infect Dis. 2020 Oct;99:291-297. doi: 10.1016/j.ijid.2020.07.081. Epub 2020 Aug 6. Int J Infect Dis. 2020. PMID: 32768693 Free PMC article.

Cited by

Mechanistic and Therapeutic Implications of Extracellular Vesicles as a Potential Link Between Covid-19 and Cardiovascular Disease Manifestations.
Pironti G, Andersson DC, Lund LH. Pironti G, et al. Front Cell Dev Biol. 2021 Feb 11;9:640723. doi: 10.3389/fcell.2021.640723. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33644077 Free PMC article.
Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein.
Gasparello J, D'Aversa E, Papi C, Gambari L, Grigolo B, Borgatti M, Finotti A, Gambari R. Gasparello J, et al. Phytomedicine. 2021 Jul;87:153583. doi: 10.1016/j.phymed.2021.153583. Epub 2021 May 4. Phytomedicine. 2021. PMID: 34033999 Free PMC article.
An integrative look at SARS‑CoV‑2 (Review).
Ortega MA, Fraile-Martínez O, García-Montero C, García-Gallego S, Sánchez-Trujillo L, Torres-Carranza D, Álvarez-Mon MÁ, Pekarek L, García-Honduvilla N, Bujan J, Álvarez-Mon M, Asúnsolo Á, De la Torre B. Ortega MA, et al. Int J Mol Med. 2021 Feb;47(2):415-434. doi: 10.3892/ijmm.2020.4828. Epub 2020 Dec 22. Int J Mol Med. 2021. PMID: 33416095 Free PMC article. Review.
Successful use of mild therapeutic hypothermia as compassionate treatment for severe refractory hypoxemia in COVID-19.
Cruces P, Cores C, Casanova D, Pizarro F, Díaz F. Cruces P, et al. J Crit Care. 2021 Jun;63:260-263. doi: 10.1016/j.jcrc.2021.01.008. Epub 2021 Jan 23. J Crit Care. 2021. PMID: 33583631 Free PMC article.
Aged garlic extract major constituent S-1-propenyl-l-cysteine inhibits proinflammatory mRNA expression in bronchial epithelial IB3-1 cells exposed to the BNT162b2 vaccine.
Papi C, Gasparello J, Marzaro G, Macone A, Zurlo M, Di Padua F, Fino P, Agostinelli E, Gambari R, Finotti A. Papi C, et al. Exp Ther Med. 2025 Jun 10;30(2):153. doi: 10.3892/etm.2025.12903. eCollection 2025 Aug. Exp Ther Med. 2025. PMID: 40529387 Free PMC article.

See all "Cited by" articles

References

1. The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. Online ahead of print. - DOI - PMC - PubMed
1. IDSE Disappointing results from first phase 3 trial of tocilizumab for COVID-19. IDSE. 2020 https://www.idse.net/Covid-19/Article/07-20/Disappointing-Results-From-F... Online ahead of print.
1. Cavalcanti A.B., Zampieri F.G., Rosa R.G., Azevedo L.C.P., Veiga V.C., Avezum A. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2019014. Online ahead of print. - DOI - PMC - PubMed
1. Cicchese J.M., Evans S., Hult C., Joslyn L.R., Wessler T., Millar J.A. Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol Rev. 2018;285(1):147–167. - PMC - PubMed
1. de Simone G., Mancusi C. COVID-19: timing is important. Eur J Intern Med. 2020;77:134–135. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information

[1] The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. Online ahead of print. - DOI - PMC - PubMed

[2] The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2021436. Online ahead of print. - DOI - PMC - PubMed

[3] IDSE Disappointing results from first phase 3 trial of tocilizumab for COVID-19. IDSE. 2020 https://www.idse.net/Covid-19/Article/07-20/Disappointing-Results-From-F... Online ahead of print.

[4] IDSE Disappointing results from first phase 3 trial of tocilizumab for COVID-19. IDSE. 2020 https://www.idse.net/Covid-19/Article/07-20/Disappointing-Results-From-F... Online ahead of print.

[5] Cavalcanti A.B., Zampieri F.G., Rosa R.G., Azevedo L.C.P., Veiga V.C., Avezum A. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2019014. Online ahead of print. - DOI - PMC - PubMed

[6] Cavalcanti A.B., Zampieri F.G., Rosa R.G., Azevedo L.C.P., Veiga V.C., Avezum A. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020 doi: 10.1056/NEJMoa2019014. Online ahead of print. - DOI - PMC - PubMed

[7] Cicchese J.M., Evans S., Hult C., Joslyn L.R., Wessler T., Millar J.A. Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol Rev. 2018;285(1):147–167. - PMC - PubMed

[8] Cicchese J.M., Evans S., Hult C., Joslyn L.R., Wessler T., Millar J.A. Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol Rev. 2018;285(1):147–167. - PMC - PubMed

[9] de Simone G., Mancusi C. COVID-19: timing is important. Eur J Intern Med. 2020;77:134–135. - PMC - PubMed

[10] de Simone G., Mancusi C. COVID-19: timing is important. Eur J Intern Med. 2020;77:134–135. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Finding the right time for anti-inflammatory therapy in COVID-19

Affiliations

Finding the right time for anti-inflammatory therapy in COVID-19

Authors

Affiliations

Figures

Comment in

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical